Growth momentum Twist Bioscience shows consistent revenue growth across multiple quarters including Q3 2026 with year-over-year increases and a strategic upsized equity offering to fund R&D and manufacturing expansion, signaling imminent capacity and product line expansion opportunities for sales of DNA synthesis, oligo pools, and related services.

Strategic partnerships Recent collaboration with Lilly’s TuneLab AI/ML drug discovery platform indicates demand for high-quality data generation and characterization services, suggesting cross-sell potential for antibody characterization, sequencing, and bioinformatics offerings to accelerate partner R&D pipelines.

Expansion funding Public offering to raise capital earmarked for manufacturing expansion and product offerings points to near-term execution on capacity increases, creating upsell opportunities in equipment, consumables, high-throughput synthesis, and related services for growing customer demand.

Market positioning Strong emphasis on synthetic DNA manufacturing and high-throughput capabilities positions Twist as a strategic supplier for life sciences, agriculture, and industrial chemicals, presenting sales openings for research reagents, custom DNA synthesis, and associated sequencing/NGS enrichment products.

Financial health signals Healthy gross margins around 52% combined with ongoing investment in R&D and manufacturing suggests a robust value proposition; sales conversations can focus on cost‑effective, scalable DNA synthesis solutions and long-term partnerships with cost of ownership benefits.